171 related articles for article (PubMed ID: 11727284)
1. Prevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet components.
Luban NL
Semin Hematol; 2001 Oct; 38(4 Suppl 11):34-45. PubMed ID: 11727284
[TBL] [Abstract][Full Text] [Related]
2. Amotosalen/UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host disease.
Castro G; Merkel PA; Giclas HE; Gibula A; Andersen GE; Corash LM; Lin JS; Green J; Knight V; Stassinopoulos A
Transfusion; 2018 Jun; 58(6):1506-1515. PubMed ID: 29607502
[TBL] [Abstract][Full Text] [Related]
3. Prevention of transfusion-associated graft-versus-host disease with pathogen-reduced platelets with amotosalen and ultraviolet A light: a review.
Cid J
Vox Sang; 2017 Oct; 112(7):607-613. PubMed ID: 28833219
[TBL] [Abstract][Full Text] [Related]
4. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment.
Grass JA; Wafa T; Reames A; Wages D; Corash L; Ferrara JL; Lin L
Blood; 1999 May; 93(9):3140-7. PubMed ID: 10216113
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA.
Grass JA; Hei DJ; Metchette K; Cimino GD; Wiesehahn GP; Corash L; Lin L
Blood; 1998 Mar; 91(6):2180-8. PubMed ID: 9490707
[TBL] [Abstract][Full Text] [Related]
6. Transfusion of pathogen-reduced platelet components without leukoreduction.
Sim J; Tsoi WC; Lee CK; Leung R; Lam CCK; Koontz C; Liu AY; Huang N; Benjamin RJ; Vermeij HJ; Stassinopoulos A; Corash L; Lie AKW
Transfusion; 2019 Jun; 59(6):1953-1961. PubMed ID: 30919465
[TBL] [Abstract][Full Text] [Related]
7. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease?
Fast LD; Nevola M; Tavares J; Reddy HL; Goodrich RP; Marschner S
Transfusion; 2013 Feb; 53(2):373-81. PubMed ID: 22612327
[TBL] [Abstract][Full Text] [Related]
8. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment.
Knutson F; Osselaer J; Pierelli L; Lozano M; Cid J; Tardivel R; Garraud O; Hervig T; Domanovic D; Cukjati M; Gudmundson S; Hjalmarsdottir IB; Castrillo A; Gonzalez R; Brihante D; Santos M; Schlenke P; Elliott A; Lin JS; Tappe D; Stassinopoulos A; Green J; Corash L
Vox Sang; 2015 Nov; 109(4):343-52. PubMed ID: 25981525
[TBL] [Abstract][Full Text] [Related]
9. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.
Roback JD; Conlan M; Drew WL; Ljungman P; Nichols WG; Preiksaitis JK
Transfus Med Rev; 2006 Jan; 20(1):45-56. PubMed ID: 16373187
[TBL] [Abstract][Full Text] [Related]
10. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
[TBL] [Abstract][Full Text] [Related]
11. Transfusion-associated graft-versus-host disease reexamined: potential for improved prevention using a universally applied intervention.
Kleinman S; Stassinopoulos A
Transfusion; 2018 Nov; 58(11):2545-2563. PubMed ID: 30267423
[TBL] [Abstract][Full Text] [Related]
12. Multilineage engraftment with minimal graft-versus-host disease following in utero transplantation of S-59 psoralen/ultraviolet a light-treated, sensitized T cells and adult T cell-depleted bone marrow in fetal mice.
Bhattacharyya S; Chawla A; Smith K; Zhou Y; Talib S; Wardwell B; Cowan MJ
J Immunol; 2002 Dec; 169(11):6133-40. PubMed ID: 12444116
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light.
Lin L; Hanson CV; Alter HJ; Jauvin V; Bernard KA; Murthy KK; Metzel P; Corash L
Transfusion; 2005 Apr; 45(4):580-90. PubMed ID: 15819680
[TBL] [Abstract][Full Text] [Related]
14. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.
van Rhenen D; Gulliksson H; Cazenave JP; Pamphilon D; Ljungman P; Klüter H; Vermeij H; Kappers-Klunne M; de Greef G; Laforet M; Lioure B; Davis K; Marblie S; Mayaudon V; Flament J; Conlan M; Lin L; Metzel P; Buchholz D; Corash L;
Blood; 2003 Mar; 101(6):2426-33. PubMed ID: 12456508
[TBL] [Abstract][Full Text] [Related]
15. Bacterial contamination of platelets for transfusion: strategies for prevention.
Levy JH; Neal MD; Herman JH
Crit Care; 2018 Oct; 22(1):271. PubMed ID: 30367640
[TBL] [Abstract][Full Text] [Related]
16. Graft-versus-host disease: introduction and prospect.
Ohto H; Suzuki H; Abe R
Fukushima J Med Sci; 1993 Dec; 39(2):63-7. PubMed ID: 7927136
[TBL] [Abstract][Full Text] [Related]
17. [Transfusion-associated graft-versus-host disease guideline on gamma irradiation of blood components].
Landi EP; de Oliveira JS
Rev Assoc Med Bras (1992); 1999; 45(3):261-72. PubMed ID: 10513059
[TBL] [Abstract][Full Text] [Related]
18. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma.
Wollowitz S
Semin Hematol; 2001 Oct; 38(4 Suppl 11):4-11. PubMed ID: 11727280
[TBL] [Abstract][Full Text] [Related]
19. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.
Lin L; Dikeman R; Molini B; Lukehart SA; Lane R; Dupuis K; Metzel P; Corash L
Transfusion; 2004 Oct; 44(10):1496-504. PubMed ID: 15383024
[TBL] [Abstract][Full Text] [Related]
20. Is pathogen reduction an acceptable alternative to irradiation for risk mitigation of transfusion-associated graft versus host disease?
Li M; Irsch J; Corash L; Benjamin RJ
Transfus Apher Sci; 2022 Apr; 61(2):103404. PubMed ID: 35288055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
